Researchers have uncovered an unexpected biological process that may allow the body to directly control stored sugar, challenging decades of scientific understanding.
People often describe anesthesia as something that puts a patient in a “deep sleep.” An anesthesiologist enters the operating room, and part of their mission is to ensure that the patient is completely unaware of what is happening around them until they wake up, often several hours later. Scientists and doctors have long debated what happens to the brain under anesthetic drugs during a surgical procedure.
A new study by Yale School of Medicine’s Departments of Anesthesiology and Neurology published on May 11, 2026, in Proceedings of the National Academy of Sciences uncovers new insights which may change the way we describe being under anesthesia. The study, “Spectral mapping reveals a resemblance of the anesthetic brain state to both sleep and coma,” reveals that being anesthetized may be more than simply being “put to sleep.” It can potentially carry more similarities to being in a coma than we originally thought.
13 years ago, a Tulane physicist told me I didn’t understand the laws of physics.
That’s why, he said, I can’t see why the Singularity is inevitable. Or why it’s perfectly compatible with Christianity.
Fair enough.
Dr. Frank J. Tipler is the cosmologist behind the Omega Point. He is a professor of mathematical physics at Tulane University, and the author of The Anthropic Cosmological Principle, The Physics of Immortality, and The Physics of Christianity.
He didn’t come on Singularity FM to soften his views. He came to defend them.
In one hour we covered:
Marc Benioff and Anthropic CEO Dario Amodei discuss the future of AI and the leadership required to ensure responsible governance and ethical deployment.
Dreamforce 2025
Dream Zero: NVIDIA’s latest paradigm where a robot “dreams” its success in a world model before executing the motor commands in reality [[06:12](https://www.youtube.com/watch?v=3Y8aq_ofEVs&t=372)].
Jim Fan, who leads the embodied autonomous research group at Nvidia, returns to AI Ascent to argue that robotics is entering its end game — and that the playbook is already written. He walks through what he calls \.
MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.
Most vaccines generate both antibodies and T cells that can target the vaccine antigen by activating antigen-presenting cells, such as dendritic cells. In this study, the researchers boosted the T-cell response with a new type of vaccine adjuvant (a material that can help stimulate the immune system). The new adjuvant consists of mRNA molecules encoding genes that turn on immune signaling pathways and promote a supercharged T-cell response.
In studies in mice, this mRNA-encoded adjuvant enabled the immune system to completely eradicate most tumors, either on its own or delivered along with a tumor antigen. The adjuvant also boosted the T-cell response to vaccines against influenza and COVID-19.
Renewable energy technologies, such as solar cells and wind turbines, are becoming increasingly widespread in many countries worldwide. Reliably storing the electricity produced by these devices, so that it can be used later at times when sunlight or wind are scarce, would further improve their effectiveness as sustainable energy solutions.
A promising solution to store solar and wind energy entails the use of aqueous zinc (Zn) metal batteries. These are low-cost, safe and environmentally friendly batteries that store and release energy, leveraging water-based solutions and Zn anodes.
Despite their potential, Zn batteries have not yet achieved the desired efficiencies and long-term stability. This is because water molecules can break down during their operation and small structures called Zn dendrites form on the surface of zinc electrodes, both of which were found to reduce performance.
Liver fibrosis is a common pathological outcome of chronic liver injury. Many therapeutic agents show limited clinical efficacy or significant adverse effects due to the complex pathogenesis of liver fibrosis. This challenge underscores the urgent need to identify potential therapeutic targets and improve existing therapies. Hepatocytes serve as pivotal initiators of liver fibrosis that actively engage in signaling crosstalk with other hepatic cell types to promote fibrogenesis. Advances in understanding hepatocyte-centered signaling crosstalk have enabled the identification of potential therapeutic targets. Furthermore, combination therapies that regulate multiple pathways and drug modifications that improve pharmacological properties may help to minimize adverse effects and enhance the efficacy of existing treatments.